Trial · NCT07890636
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
NCT07890636, Phase 2, Not yet recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC. Trials, record NCT07890636. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890636
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
- NCT number
- NCT07890636
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 64 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Lung Neoplasm Malignant
- Interventions
- Adebrelimab, Adjuvant treatment
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-Year Disease-Free Survival (DFS) Rate | Up to 2 years from the first dose of study treatment. | The 2-year DFS rate is defined as the probability of patients remaining alive without disease recurrence or metastasis at 2 years from the first dose of postoperative adjuvant treatment with adebrelimab and famitinib. |
| Secondary | Disease-Free Survival (DFS) | From the first dose of study treatment, assessed up to 3 years. | DFS is defined as the time from the first dose of postoperative adjuvant treatment to the first documented disease recurrence, metastasis, or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | From the first dose of study treatment, assessed up to 3 years. | OS is defined as the time from the first dose of postoperative adjuvant treatment to death from any cause. Patients who are alive at the last follow-up will be censored at the date they were last known to be alive. |
| Secondary | Safety | From informed consent to 30 days after the last dose for AEs, and up to 90 days after the last dose for SAEs/AESIs. | The incidence and severity of treatment-related adverse events (TRAEs), serious adverse events (SAEs), and clinically significant laboratory abnormalities will be assessed. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890636
GET https://conductscience.org/api/trials/v1/NCT07890636/registered